Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BGI Americas Corp. is currently navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is handled by 1 distinct examiner within 1 distinct art unit. The limited number of active cases suggests a specific focus for the company's current patent strategy, with all activity concentrated in one administrative group.
The busiest examiner, GROSS, CHRISTOPHER M, is assigned 1 pending office action. This single action constitutes the whole of the company's pending office actions. With only 1 distinct art unit involved, the company's prosecution is subject to the standards of one specific administrative group. Practitioners should carefully analyze the past decisions of GROSS, CHRISTOPHER M to effectively manage this Biotechnology & Pharmaceuticals filing.
Because the busiest examiner, GROSS, CHRISTOPHER M, handles the 1 pending office action, there is no internal data to compare examiner behavior within the portfolio. The presence of 1 distinct examiner and 1 distinct art unit creates a centralized prosecution environment. Success in the Biotechnology & Pharmaceuticals field for this company depends on tailoring the approach to the specific requirements and interpretive style of this single official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GROSS, CHRISTOPHER M | 1 | 63.5% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18487926 | MULTIPLE TAGGING OF INDIVIDUAL LONG DNA FRAGMENTS | GROSS, CHRISTOPHER M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18487926 | MULTIPLE TAGGING OF INDIVIDUAL LONG DNA FRAGMENTS | GROSS, CHRISTOPHER M | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18487926 | MULTIPLE TAGGING OF INDIVIDUAL LONG DNA FRAGMENTS | GROSS, CHRISTOPHER M | 1684 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBGI Americas Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christopher M Gross has the most, with 1 of BGI Americas Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
